Last reviewed · How we verify
Alcaftadine 0.25%
At a glance
| Generic name | Alcaftadine 0.25% |
|---|---|
| Also known as | Lastacaft® |
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea
- Safety and Efficacy Study of a Eye Drop for Eye Allergy (PHASE3)
- A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis (PHASE4)
- Ocular Allergy Treatment Practical Impact Trial (PHASE4)
- A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |